Korea Institute of Science and Technology

Postech Academy-industry Foundation

Sml Biopharm Co, Ltd.

Gyo Chang Keum

Ae Nim Pae

Eun Kyoung Bang

Kyung Il Choi

Hyunah Choo

Jae Kyun Lee

Seon Hee Seo

Eunice Eun-Kyeong Kim

Youngsoo Kim

Dong Jin Kim

Yong Seo Cho

Hyewhon Rhim

Soon Bang Kang

Hee Sup Shin

Eun Joo Roh

Sung Key Jang

Yong Koo Kang

Ghil Soo Nam

Kye Jung Shin

Hesson Chung

Hyun Ah Choo

Key-Sun Kim

Hee Sun Kim

Ghilsoo Nam

Dong Yun Shin

Hye Jin Chung

Kee Dal Nam

Hoh Gyu Hahn

Chan Seong Cheong

Kee Hyun Choi

Yoon Jee Kim

Woong Seo Park

Hye Ran Kim

Jung Hyun Kim

Youngjae Kim

Yun Kyung Kim

Jin Bum Kim

Byung Sun Jeon

Jin Hyeong Park

Hee Won Jin

Chi Man Song

Taek Chan Kang

Sung Su Lim

Juhyeon Lee

Cheolju Lee

Mi Young Yeom

Eunice Eun Kyeong Kim

Jin Sook Kwak

Hua Li

Suyeon Yeom

SeungGi Lee

Jae Hwan Nam

An Soo Lee

Ashraf Kareem El-Damasy

Seo Hyeon Bae

Ahmed A Elbatrawy

Taek Kang

Disclosed is a novel composition of lipid nanoparticles for stabilizing a nucleic acid drug and enhancing delivery in vivo. Lipid nanoparticles include a nucleic acid drug and a lipid, and the nucleic acid includes all of mRNA-based vaccines, RNA for immune boosters, miRNA, siRNA, pDNA, antisense ODN, and pDNA. The lipid of nanoparticles includes a trehalose-based lipid, an ionizable lipid, a phospholipid, a PEG-lipid, and a structure-maintaining lipid. The structure-maintaining lipid provides a composition that can replace commonly used cholesterol with a lithocholic acid derivative, a glycyrrhetinic acid derivative, or a diosgenin derivative. The lipid nanoparticles can be used as a vaccine or therapeutic agent, depending on the type of nucleic acid drug that is used.

Pharmaceutical composition of lipid nanoparticle for delivering nucleic acid drug containing trehalose derivative and novel structure-maintaining lipid compound

Disclosed are a compound with near-infrared fluorescence that selectively binds to tau aggregates, a method for preparing the same, a tau-targeting near-infrared fluorescent probe including the compound, a composition for detecting a tau fiber protein containing the near-infrared fluorescent probe as an active ingredient, and the use of the composition for the diagnosis of tauopathy. In particular, the compound does not bind to an amyloid beta protein and has high selectivity to a tau aggregate, specifically reported as an etiology of the initial state of tauopathy, thus being useful as a near-infrared fluorescent detector for detecting a tau fiber protein for early diagnosis of a tauopathy including Alzheimer's disease.

Compounds useful as near-infrared fluorescent probes selectively binding to tau aggregates and method of preparing the same

Disclosed are a compound selected from novel indazole derivatives, pharmaceutically acceptable salts thereof, hydrates thereof and stereoisomers thereof, a method for preparing the compound, and a pharmaceutical composition for preventing, alleviating or treating cancer containing the compound as an active ingredient. The novel indazole derivatives exhibit excellent ABL/DDR1 inhibitory efficacy and anti-proliferative efficacy against cancer cells, specifically blood cancer cells, and inhibitory activity against ABL T315I point mutations, thus being useful for the prevention, alleviation or treatment of cancer, specifically blood cancer, especially chronic myelogenous leukemia.

Indazole derivatives and pharmaceutical composition for preventing, alleviating or treating cancer containing the same

The present invention relates to a carbazole compound having anti-virus activity, and more particularly, to a novel compound selected from the group of consisting of a carbazole compound which shows excellent anti-proliferative efficacy against hepatitis C virus (HCV), a pharmaceutically acceptable salt thereof, a hydrate thereof, and an isomer thereof; an anti-virus pharmaceutical composition including the novel compound as an active ingredient; a pharmaceutical composition for preventing or treating liver diseases caused by hepatitis C virus; and a method of preparing the novel compound.

Carbazole compound having anti-virus activity

Provided herein are a novel Zn-DPA complex compound and an siRNA delivery system including the same as a transporter, the Zn-DPA complex compound including: a phosphate-directing functional part of zinc (II)-dipicolylamine ('Zn-DPA'); a cell membrane-directing functional part; and a linker part that links the phosphate-directing functional part and the cell membrane-directing functional part. The Zn-DPA complex compound has low toxicity and efficiently delivers siRNA to cells, thereby useful in various ways for various studies and diagnosis and treatment of diseases, which use siRNA.

Zn-DPA complex compounds and siRNA delivery systems containing the same

The present invention provides a carbazole derivative represented by Formula 1: wherein X is CHor C(O), Y is selected from NRR, piperidinyl groups in which two of the carbon atoms are substituted with Rand R, piperazinyl groups in which the nitrogen atom is substituted with R, and morpholinyl groups, n is an integer from 2 to 5, Rand R, which may be identical or different, are each independently selected from C-Calkyl, phenyl, and benzyl, with the proviso that Rand Rmay be bonded together to form a ring, Rand R, which may be identical or different, are each independently selected from hydrogen, C-Calkyl, phenyl, and benzyl, and Ris selected from C-Calkyl, C-Calkylcarbonyl, phenyl substituted with C-Calkyloxy, hydroxyphenyl, benzyl, and benzoisoxazol-3-yl; or a pharmaceutically acceptable salt thereof.

Carbazole derivatives acting on 5-HT7 receptor

The present invention relates to oxazolidinone compounds represented by Chemical Formula 1, pharmaceutically acceptable salts thereof or hydrates, a method of preparing the same, and a pharmaceutical composition for preventing or treating Hepatitis C infection: 

Oxazolidinone derivatives and composition for preventing or treating hepatitis C containing the same

The present invention relates to a 6-pyrazolylamido-3-substituted azabicyclo[3.1.0]hexane derivatives useful as calcium channel blockers, pharmaceutically acceptable salts thereof and medical use of the calcium channel inhibiting effect of the compounds for treatment of diseases.

6-pyrazolylamido-3-substituted azabicyclo[3.1.0]hexane compounds as calcium channel inhibitors

Disclosed are novel imidazolylalkylcarbonyl derivatives useful as calcium channel modulators and a preparation method of the same. Also disclosed is a method for the treatment of diseases by administering the above compounds based on their inhibitory activity against calcium channel.

Imidazolylalkylcarbonyl derivatives as calcium channel modulators and preparation method thereof

The present invention relates to pyrazolylmethylamine-piperazine derivatives and their pharmaceutically acceptable salts effective as calcium channel modulators and a method of manufacturing the same. The present invention also relates to the medicinal use of the above compounds as therapeutic treatment of diseases due to their effect as calcium channel modulators.

Pyrazolylmethylamine compounds as calcium channel modulators and preparation method thereof

Growing community of inventors

Seoul, South Korea

Gyo Chang Keum